Download PDF
Drug Res (Stuttg) 2021; 71(07): 355-362
DOI: 10.1055/a-1481-7879
Review

Exploring Azatidinone Moiety: An Insight into its Anti-tubercular Potency

Rina Das 
1   MMCP, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
,
Dinesh Kumar Mehta 
1   MMCP, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
,
Meenakshi Dhanawat
1   MMCP, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

TB is becoming a worldwide problem and it was declared since 1993 by the World Health Organization (WHO), a global health emergency. The current problem of tuberculosis therapy is the emergence of multi-drug resistant (MDR) strains, caused by the improper use of antibiotics in chemotherapy of TB patients. Azatidinones, a β-lactam cyclic amide with four atoms in a ring, has been considered as a magic moiety (wonder nucleus) which possesses almost all types of biological activities. This diversity in the biological response profile has attracted the attention of many researchers to explore this skeleton to its multiple potential against several activities. Present article is sincere attempt to review chemistry, method of synthesis of azatidinones and to study azatidinones synthesized in last few years which have shown potent antitubercular activity.

Key words

antitubercular activity - azatidinones - β-lactam cyclic amide - tuberculosis (TB) - multi-drug resistant - antitubercular drugs


Publication History

Received: 27 December 2020

Accepted: 12 April 2021

Article published online:
25 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 MVN DeSouza. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr Opin Pulm Med 2006; 12: 167-171
    CrossrefPubMedGoogle Scholar
  • 2 De Souza MVN. Promising drugs against tuberculosis in recent past. Anti-Infect. Drug Discovery 2006; 1: 3344-3349
    PubMedGoogle Scholar
  • 3 Swamy BN, Suma TK, Rao GV. et al. Synthesis of isonicotinoylhydrazones from anacardic acid and their in-vitro activity against Mycobacterium smegmatis. Eur J Med Chem 2007; 42: 420-424
    CrossrefPubMedGoogle Scholar
  • 4 Janin YL. Antituberculosis drugs: Ten years of research. Bioorg Med Chem 2007; 15: 2479-2513
    CrossrefPubMedGoogle Scholar
  • 5 Scior T, Garces. Eisele SJ. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: A critical review. Curr Med Chem 2006; 13: 2205-2219
    CrossrefPubMedGoogle Scholar
  • 6 Ballell L, Field RA, Duncan K. et al. New small-molecule synthetic antimycobacterials. Antimicrob Agents and Chemotherapy 2005; 49: 2153-2163
    CrossrefPubMedGoogle Scholar
  • 7 Sriram D, Bal TR, Yogeeswari P. Newer aminopyrimidinimino isatin analogues as non-nucleoside HIV-1 reverse transcriptase inhibitors for HIV and other opportunistic infections of AIDS: Design, synthesis and biological evaluation. Il Farmaco 2005; 60: 377-384
    CrossrefPubMedGoogle Scholar
  • 8 Berry M, Kon OM. Multidrug and extensively drug-resistant tuberculosis: an emerging threat. Eur Respir Rev 2009; 18: 195-197
    CrossrefPubMedGoogle Scholar
  • 9 Szekely R, Waczek F, Szabadkai I. et al A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signaling. Immunology Letters 2008; 116: 225-231
    CrossrefPubMedGoogle Scholar
  • 10 Somu RV, Boshoff H, Qiao C. et al. Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of mycobacterium tuberculosis . J Med Chem 2006; 49: 31-34
    CrossrefPubMedGoogle Scholar
  • 11 Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis . Nat Rev Microbiol 2008; 6: 41-52
    CrossrefPubMedGoogle Scholar
  • 12 Snider JDE, Castro KG. The global threat of drug-resistant tuberculosis. Eng J Med 1998; 338: 1689-1690
    CrossrefPubMedGoogle Scholar
  • 13 Global Tuberculosis Control: Surveillanc e, Planning, Financing WHO Report 2008; 51-54
    PubMed
  • 14 Ruiz SMJ, Alcala L, Martinez L. et al In-vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-2568
    CrossrefPubMedGoogle Scholar
  • 15 Smith CV, Sharma V, Sacchettini JC. et al TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis 2004; 84: 45-55
    CrossrefPubMedGoogle Scholar
  • 16 Sullivan EA, Kreiswirth BN, Palumbo L. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-1150
    CrossrefPubMedGoogle Scholar
  • 17 Teodori E, Dei S, Scapecchi S. et al. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco 2000; 57: 385-415
    CrossrefPubMedGoogle Scholar
  • 18 Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-577
    CrossrefPubMedGoogle Scholar
  • 19 Omar A, Ahmed MA. Synthesis of some new 3H-quinazolin-4-one derivatives as potential antitubercular agents. World Appl Sci. Journal 2008; 5: 94-99
    PubMedGoogle Scholar
  • 20 O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-1058
    CrossrefPubMedGoogle Scholar
  • 21 Glickman SW, Rasiel EB, Hamilton CD. et al. A portfolio model of drug development for tuberculosis. Science 2006; 311: 1246-1247
    CrossrefPubMedGoogle Scholar
  • 22 Tomioka H. Prospects for development of new antituberculous drugs. Kekkaku 2002; 77: 573-584
    PubMedGoogle Scholar
  • 23 Duncan K, Barry CE. Prospects for new antitubercular drugs. Curr. Opin Microbiol. 2004; 7: 460-465
    CrossrefPubMedGoogle Scholar
  • 24 Manhas MS, Bose AK. Synthesis of penicillin and cephalosporin C and Analogs. Marcel Dekker; New York: 1969: 13
    Google Scholar
  • 25 Mukerjee AK, Singh AK. β-lactams: Retrospect and prospect. Tetrahedrons 1978; 34: 1731
    CrossrefPubMedGoogle Scholar
  • 26 Morin RB, Gorman M. Chemistry and Biology of b-Lactam Antibiotics. Academic; New York: 1982: 1-3
    Google Scholar
  • 27 De Kimpe N. Comprehensive Heterocyclic Chemistry-II; Katritzky, A. R., Rees, C. W., Scriven, E. V. F., Padwa, A., Eds. Pergamon; Oxford: 1996. Vol. 1B. 507
    Google Scholar
  • 28 Singh GS, Singh T, Lakhan R. Synthesis 13C-NMR and anticonvulsant activity of new isatin-based spiroazetidinones. Indian J. Chem. 1997; 36(B) 951
    PubMedGoogle Scholar
  • 29 Barrett AGM, Baugh SPD, Gibson VC. et al. Highly functionalised monocyclic and bicyclic β-lactams via alkene metathesis. Chem. Commun. 1997; 155
    CrossrefPubMedGoogle Scholar
  • 30 Shindo M, Oya S, Sato Y. et al. Cycloaddition of lithium ynolate to imines: Synthesis of 3,4-disubstituted β-lactams. Heterocycles 1998; 49: 113
    CrossrefPubMedGoogle Scholar
  • 31 De Risi C, Pollini GP, Veroneze AC. et al. A new simple route for the synthesis of (±)-2-azetidinones starting from β-enaminoketoesters. Tetrahedron Lett 1999; 40: 6995
    CrossrefPubMedGoogle Scholar
  • 32 Naskar D, Roy S. Synthesis of a-bromo-lactam via a novel catalytic Hunsdiecker like protocol. J. Chem. Soc. Perkin Trans 1999; 1: 2435
    CrossrefPubMedGoogle Scholar
  • 33 Silverstein RM, Bassler GC, Morrill TC. Spectrometric Identification of Organic Compounds. 4th Ed. John Wiley and Sons; New York, U.S.A: 1981: 117-127
    Google Scholar
  • 34 Pavia DL, Lampman GM, Kriz GS. Introduction to Spectroscopy: A Guide for Students of Organic Chemistry. Saunders College Publishing; Orlando, Florida, U.S.A.: 1979
    Google Scholar
  • 35 Staudinger H, Enke F. Die Ketene, Stuttgart,F publictn, Germany. 1912
    PubMedGoogle Scholar
  • 36 Joyeau R, Molines H, Labia R. et al. N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases. J. Med. Chem. 1988; 31: 370
    CrossrefPubMedGoogle Scholar
  • 37 Manhas MS, Chawla HPS, Amins G. et al. Studies on Lactams. Synthesis. 1977; 6: 407
    PubMedGoogle Scholar
  • 38 Bose AK, Banik BK, Manhas MS. Stereocontrol of β-lactam formation using microwave irradiation. Tetrahedron Lett 1995; 36: 213
    PubMed
  • 39 Bose AK, Chiang YH, Manhas MS. One step synthesis of α-amido-β-lactams. Tetrahedron Lett 1973; 14: 2503-2506
    CrossrefPubMedGoogle Scholar
  • 40 Patel P, Korgaokar S, Parikh K. et al. Synthesis and biological activity of 2 azetidinones, sulphonamides, arylamides and thiourea derivatives. IJC,38(B) 1999; 696-700
    PubMedGoogle Scholar
  • 41 Kaythara P, Upadhayay T, Doshi R. et al. Synthesis of some 2-azetidinones as a potential anti- tubercular agents. Indian Journal of Heterocyclic Chemistry 2000; 10: 09-12
    PubMedGoogle Scholar
  • 42 Khyati PA, Oza PS, Bhatt SB. et al. Synthesis of some new 2 azetidinones as potential anti tubercular agents. Indian Journal of Chemistry. 2000; 39(B) 716-718
    PubMedGoogle Scholar
  • 43 Thakar KM, Kachhadia VV, Joshi HS. Synthesis of 4- thiazolidinones and 2-azetidinones bearing benzo (b) thiophene nucleus as potential antitubercular and antimicrobial agents. Indian Journal of Chemistry. 2003; 42(B) 1544-1547
    PubMedGoogle Scholar
  • 44 Patel RB, Desai PS, Desai KR. et al. Synthesis of pyrimidine based thiazolidinones and azetidinones : antimicrobial and antitubercular agents. Indian Journal of Chemistry. 2006; 45(B) 773-778
    PubMedGoogle Scholar
  • 45 Basawaraj R, Amith L, Vijay T. et al. Synthesis and Antitubercular Activities of Azetidinone and Thiazolidinone Derivatives from 5-Chloro-3-Methylbenzofuran. International Journal of ChemTech Research 2010; 2: 1764-1770
    PubMedGoogle Scholar
  • 46 Dighe RD, Rohom SS, Deshpande MM. et al. Microwave assisted synthesis and evaluation of isatinyl thiazole derivatives as anti-Mycobacterium tuberculosis agents and dTDP-rhamnose inhibitors. IJRPBS 2011; 2: 776
    PubMedGoogle Scholar
  • 47 Ilango K, Arunkumar S. Synthesis, Antimicrobial and Antitubercular Activities of Some Novel Trihydroxy Benzamido Azetidin-2-one Derivatives. Tropical Journal of Pharmaceutical Research 2011; 10: 219-229
    CrossrefPubMedGoogle Scholar
  • 48 Rajasekaran M, Periasamy. Venkatesan S. Synthesis, characterization and biological activity of some novel azetidinones. Journal of Developmental Biology and Tissue Engineering 2010; 2: 5-13
    PubMedGoogle Scholar
  • 49 Ayarivan,Puratchikody.; Ramalakshmi,Natarajan.;Mohanapriya,Jayapal.;Mukesh Doble. Synthesis, In-vitro Antitubercular Activity and 3D-QSAR of Novel Quinoxaline Derivatives. Chem Biol Drug Des 2011; 78: 988-999
    CrossrefPubMedGoogle Scholar
  • 50 Himaja M. Karigar,Asif. Synthesis of novel azetidinones derivatives as anti tubercular agents. Letters in Drug Design and Discovery 2012; 9: 611-617
    CrossrefPubMedGoogle Scholar
  • 51 Jaya P, Preethi K, Bindu Sree K. et al. Synthesis, Characterization and Its Biological Evaluation of Some Novel 4-Thiazolidinone and 2-Azetidinone Derivatives. Asian. J. Pharm. Res 2012; 2: 63-70
    PubMedGoogle Scholar
  • 52 Mohite PB, Bhaskar VH. In-vitro evaluation of tetrazoles as a novel class of anti-mycobacterium tuberculosis agents. Advanced Pharmaceutical Bulletin 2012; 2: 31-36
    PubMedGoogle Scholar
  • 53 Ritu Sharma, Pushkal Samadhiya, Srivastava S.D. et al. Synthesis and pharmaceutical importance of 2-azetidinone derivatives of phenothiazine. J. Chem. Sci. 2012; 124: 633-637
    CrossrefPubMedGoogle Scholar
  • 54 Pathak RB, Chovatia PT, Parekh HH. Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Bioorg Med Chem Lett 2012; 22: 5129-5133
    CrossrefPubMedGoogle Scholar
  • 55 Myangar KN, Akhaja TN, Naik DR. et al. Synthesis of novel azetidinyl-3-( isonicotinamide-yl)-6-iodo-quinazolin-4-ones as antimicrobial and antitubercular agents .IJPSN 2012; 5: 1735
    PubMed
  • 56 Pushkal Samadhiya, Ritu Sharma, Santosh K, Srivastava A, Savitri DSrivastava. Synthesis of 2-oxoazetidine derivatives of 2-aminothiazole and their biological activity. J. Serb. Chem. Soc 2012; 77: 599-605
    CrossrefPubMedGoogle Scholar
  • 57 Saundane AR, Walmik P. Synthesis, Antioxidant, Antimicrobial, Antimycobacterial, and Cytotoxic Activities of Azetidinone and Thiazolidinone Moieties Linked to Indole Nucleus. Journal of Chemistry 2013; 1-9
    CrossrefPubMedGoogle Scholar
  • 58 Patel NB, Pathak KK. Pyridoquinolones containing azetidinones: synthesis and their biological evaluation. Med chem. Res. 2012; 21: 2044-2055
    CrossrefPubMedGoogle Scholar
  • 59 Joshi SD, More UA, Parkale D. et al Design, synthesis of quinolinyl Schiff bases and azetidinones as enoyl ACP-reductase inhibitors. Med Chem Res 24 2015; 3892-391
    CrossrefPubMedGoogle Scholar
  • 60 Thomas B, Harindran J. Design, synthesis and evaluation of antitubercular activity of amino azetidinones from isoniazid. Int J Pharm Sci Res 2016; 7: 2795-04
    PubMedGoogle Scholar
  • 61 Sarkar S. Design, Synthesis, and evaluation of antitubercular activity of novel benzothiazole-containing an azetidinone ring. Istanbul J Pharm 2018; 48: 28-31
    CrossrefPubMedGoogle Scholar
  • 62 Dadlani Vedika, Tripathi Pushpendra, Somani Rakesh. Design, molecular docking and in-silico analysis of novel thiadiazole-azetidinone hybrids as potential antitubercular agents. Int J of Resh in Pharmaceutical Sciences 2019; 10: 3694-3703
    CrossrefPubMedGoogle Scholar
  • 63 Suresh SK, Arun S, Shrinivas DJ, Siddappa A.Patil. Design. synthesis, molecular docking and biological activity studies of novel coumarino-azetidinones, J of Molecular Structure 2021; 1231: 130016
    PubMed
  • 64 Vaijinath AV, Anand RS, Rajkumar SM. et al. Synthesis, biological evaluation and docking studies of some new indolyl-pyridine containing thiazolidinone and azetidinone analogs. Polycyclic aromatic compounds 2020; DOI: 10.1080/10406638.2020.1786706.
    CrossrefPubMedGoogle Scholar
  • 65 Nimbalkar UD, Seijas JA, Borkute R. Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) benzamide as challenging anti-tubercular scaffold. Molecules 2018; 23: 1945. DOI: 10.3390/molecules23081945.
    CrossrefPubMedGoogle Scholar